Suppr超能文献

在tau蛋白病小鼠模型中tau蛋白的体内周转分析。

Analysis of in vivo turnover of tau in a mouse model of tauopathy.

作者信息

Yamada Kaoru, Patel Tirth K, Hochgräfe Katja, Mahan Thomas E, Jiang Hong, Stewart Floy R, Mandelkow Eva-Maria, Holtzman David M

机构信息

Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.

Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, 63110, USA.

出版信息

Mol Neurodegener. 2015 Oct 26;10:55. doi: 10.1186/s13024-015-0052-5.

Abstract

BACKGROUND

Intracellular accumulation of tau as neurofibrillary tangles (NFTs) is the hallmark of Alzheimer's disease (AD) as well as in other tauopathies. Tau is present not only in the cytoplasm but also in the extracellular space such as cerebrospinal fluid (CSF) and brain interstitial fluid (ISF). Although clearance is one critical parameter leading to such intracellular/extracellular tau accumulation, in vivo turnover of tau has not been well characterized. The current study has attempted to precisely determine in vivo turnover rates of tau utilizing tet-off regulatable mice. In particular, we assessed intracellular tau and extracellular tau, soluble tau, insoluble tau and phosphorylated tau at certain sites utilizing a combination of in vivo microdialysis, biochemical analysis and specific ELISAs recognizing each species. To examine the effect of a tauopathy-associated mutation on tau clearance, half-lives of various tau species were compared between the mice with a FTDP-17 mutation that induces β-sheet formation, ΔK280 mutation (pro-aggregant mice) and control mice with additional β-sheet breaking mutations (anti-aggregant mice).

RESULTS

Here we report that tau is metabolized at much slower turnover rates in vivo than in cell culture. We found that insoluble tau in pro-aggregant mice had a significantly slower half-life (t1/2 = ~34.2 days) than soluble tau (t1/2 = ~9.7 days). In contrast, soluble tau phosphorylated in the proline rich region was cleared faster than total soluble tau. When comparing pro-aggregant mice to anti-agregant mice, turnover rates of soluble tau species were not significantly different.

CONCLUSIONS

The current study provides a comprehensive description of in vivo turnover of various tau species present in mice that express human tau. The turnover rate of soluble tau was not significantly altered between pro-aggregant mice and anti-aggregant mice. This suggests that altered conformation by ΔK280 does not have a major impact on clearance pathways for soluble tau. In contrast, different tau species displayed different half-lives. Turnover was significantly delayed for insoluble tau whereas it was accelerated for soluble tau phosphorylated in the proline rich region. These differences in susceptibilities to clearance suggest that aggregation and phosphorylation influences tau clearance which may be important in tau pathogenesis.

摘要

背景

tau蛋白以神经原纤维缠结(NFTs)的形式在细胞内积聚是阿尔茨海默病(AD)以及其他tau蛋白病的标志。tau蛋白不仅存在于细胞质中,也存在于细胞外空间,如脑脊液(CSF)和脑间质液(ISF)。尽管清除是导致这种细胞内/细胞外tau蛋白积聚的一个关键参数,但tau蛋白在体内的周转率尚未得到很好的表征。当前的研究试图利用四环素调控小鼠精确测定tau蛋白在体内的周转率。特别是,我们利用体内微透析、生化分析和识别每种tau蛋白种类的特异性酶联免疫吸附测定(ELISA)相结合的方法,评估了细胞内tau蛋白和细胞外tau蛋白、可溶性tau蛋白、不溶性tau蛋白以及特定位点的磷酸化tau蛋白。为了研究tau蛋白病相关突变对tau蛋白清除的影响,我们比较了诱导β折叠形成的FTDP - 17突变小鼠、ΔK280突变小鼠(促聚集小鼠)和具有额外β折叠破坏突变的对照小鼠(抗聚集小鼠)中各种tau蛋白种类的半衰期。

结果

我们在此报告,tau蛋白在体内的代谢周转率比在细胞培养中慢得多。我们发现促聚集小鼠中的不溶性tau蛋白半衰期(t1/2 = 约34.2天)明显比可溶性tau蛋白(t1/2 = 约9.7天)慢。相反,富含脯氨酸区域磷酸化的可溶性tau蛋白比总可溶性tau蛋白清除得更快。将促聚集小鼠与抗聚集小鼠进行比较时,可溶性tau蛋白种类的周转率没有显著差异。

结论

当前的研究全面描述了表达人tau蛋白的小鼠体内各种tau蛋白种类的周转率。促聚集小鼠和抗聚集小鼠之间可溶性tau蛋白的周转率没有显著改变。这表明ΔK280引起的构象改变对可溶性tau蛋白的清除途径没有重大影响。相比之下,不同的tau蛋白种类表现出不同的半衰期。不溶性tau蛋白的周转率明显延迟,而富含脯氨酸区域磷酸化的可溶性tau蛋白的周转率加快。这些清除敏感性的差异表明聚集和磷酸化影响tau蛋白的清除,这可能在tau蛋白病发病机制中很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/4621881/ec76096865a3/13024_2015_52_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验